[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Dr. Guido Tricot discusses myeloma stem cell research and published results of clinical trials

Dr. Guido Tricot discusses myeloma stem cell research and published results of clinical trials image

Dr. Guido Tricot discusses myeloma stem cell research and published results of clinical trials

Podcast
event Jul 12, 2013 / 11:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Dr. Guido Tricot, MD, PhD, Holden Cancer Center, University of Iowa Interview Date: July 12, 2013

Dr. Tricot discusses his investigation into ways of finding and treating the remaining cells (myeloma stem cells) that still can exist after typical treatments of transplantation and combination therapies. He discusses how immunotherapies will be used in combination with existing treatments and how with the upcoming ability to personalize treatment based on genetics, we may be able to separate out patients that need intensive treatment and those that can be cured without intensive treatment based on their myeloma's characteristics. He cites the most recent results from tandem transplantation protocols with a review of how therapies can be advanced beyond transplantation.

Schedule & Agenda

Event panelist Dr. Guido Tricot & Jenny Ahlstrom
11:00 AM
Discussion
Dr. Guido Tricot & Jenny Ahlstrom

Speakers & Moderators

The panelist Dr. Guido Tricot
Dr. Guido Tricot

Dr. Tricot's most recent clinical studies focus on not only attacking myeloma cells but also the microenvironment that supports the survival and growth of myeloma cells. His work aims at finding treatments that are non-cross-resistant with current chemotherapy and therefore can eradicate the drug-resistant myeloma cells. His work on detailed genetics of myeloma cells should allow individualized therapies to ensure the greatest efficacy, while minimizing toxicity. Over the last 15 years, the median survival for patients newly diagnosed with myeloma has, in large part due to this work, increased from 2.5 to more than 10 years. The complete remission rate has increased from 5% to 80% and one third of all patients are still in complete remission at 10 years. He received his medical degree from Catholic University of Leuven and has been in practice for more than 20 years.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Myelofibrosis Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.